CanSino Biologics reports robust growth in Q1 performance; full lifecycle layout unlocks long-term value potential

CanSino Biologics Reports Steady Growth in Q1 Performance; Full Lifecycle Portfolio Unlocks Long-Term Value Potential

CanSino Biologics (688185.SH/06185.HK) released its first-quarter financial report for 2026 on April 28. The report shows that the company achieved operating revenue of 190 million yuan in Q1, a year-on-year increase of 38.73%, demonstrating strong operational resilience under the strategies of core product volume expansion and cost reduction/efficiency improvement. Although short-term profits are under pressure, the steady growth in operating revenue has still laid a solid foundation for the recovery of full-year performance.

Specifically, MenHibix®, as China's first quadrivalent meningococcal conjugate vaccine, maintained a relatively high level of sales revenue compared to the same period last year. The successful launch of the 13-valent pneumococcal polysaccharide conjugate vaccine, Youpeixin®, has also contributed significant revenue to the Group. Meanwhile, international technology transfer and intermediate product sales are gradually becoming new revenue growth points for the Group.

As a leading innovative bacterial vaccine company in China, CanSino Biologics, leveraging its five core technology platforms—viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, and formulation and delivery technologies—has built a differentiated product portfolio covering multiple areas such as meningitis, pneumonia, DTP, effectively solving the "single-product dependency" problem faced by traditional vaccine companies.

Overall, after its approved age extension to 6 years old, the market penetration of China's first quadrivalent meningococcal conjugate vaccine, MenHibix® (MCV4), continues to increase, maintaining steady growth. China's first 13-valent pneumococcal conjugate vaccine using CRM197+TT dual-carrier protein technology, Youpeixin® (PCV13i), has seen rapid volume expansion post-launch and has become a new engine for performance growth. Furthermore, Pankangxin®, the acellular pertussis (three-component) combined vaccine for infants and young children just approved by the company in April 2026, fills a gap in the domestic market with its technological generational advantage, further improving the company's layout in the infant and child vaccine field.

It is worth mentioning that the company is actively implementing the "full lifecycle immunization" concept, accelerating the R&D and clinical progress of pipelines such as the adolescent and adult component DTP vaccine Tdcp and the 24-valent pneumococcal polysaccharide conjugate vaccine, aiming to extend its product line to the adult market, thereby breaking the ceiling of a single market segment.

In terms of internationalization strategy, the company adheres to the dual-drive approach of "Innovation + Global Market," accelerating the upgrade from "product going global" to "system going global." Currently, MenHibix® has achieved its first launch and initiated supply in Indonesia, and the production bases for both MenHibix® and Youpeixin® have obtained PIC/S GMP certification in Malaysia. This comprehensive global model covering product registration, localized production, and technology transfer will open up vast overseas market space for the company.

Looking ahead, with the continuous volume expansion of core products and the gradual realization of the full lifecycle product pipeline, CanSino Biologics' long-term value is expected to be revalued under the dual drivers of performance growth and global layout.